The biotech firm will issue approximately 229.1 million pre-funded warrants, priced at roughly 87 cents each. Additionally, the agreement includes warrants to purchase another 229.1 million shares at the same price point. This significant influx of liquidity follows a period of steady growth for the stock, which had already gained 12% over the previous three months.

Commercial Transition and Clinical Trials

Management intends to use the proceeds to fund the company’s evolution into a fully integrated commercial entity. This shift comes at a pivotal moment for Immunic’s lead candidate, vidofludimus calcium. The company is currently finalizing a Phase 3 trial of the drug for relapsing multiple sclerosis, a move that could significantly alter its market positioning if results are favorable.

Beyond its current trials, the company is preparing to expand its clinical footprint. According to the company's roadmap, the upcoming objectives include:

• Completion of the current Phase 3 relapsing multiple sclerosis study.
• Initiation of a new Phase 3 trial targeting primary progressive multiple sclerosis.
• Scaling of internal infrastructure to support eventual market entry.

The stock reached $1.051 per share in early trading, reflecting investor confidence in the company's ability to transition from development to commercialization.